Karl J. Puttlitz

Array ( [id] => 19700107 [patent_doc_number] => 12194106 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-14 [patent_title] => Antibodies targeting LIV-1 and uses thereof [patent_app_type] => utility [patent_app_number] => 18/656166 [patent_app_country] => US [patent_app_date] => 2024-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 23447 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 139 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18656166 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19432547 [patent_doc_number] => 20240301045 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-12 [patent_title] => ANTIBODY AGAINST ADVANCED GLYCATION END PRODUCTS AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/648976 [patent_app_country] => US [patent_app_date] => 2024-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27887 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 128 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18648976 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19799028 [patent_doc_number] => 20250064953 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-27 [patent_title] => Antibody, Linkers, Payload, Conjugates and Applications Thereof [patent_app_type] => utility [patent_app_number] => 18/620025 [patent_app_country] => US [patent_app_date] => 2024-03-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28556 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18620025 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19379256 [patent_doc_number] => 20240269126 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-15 [patent_title] => COMBINATION THERAPY FOR TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 18/421550 [patent_app_country] => US [patent_app_date] => 2024-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 84250 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18421550 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19563564 [patent_doc_number] => 12138315 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-11-12 [patent_title] => Anti-CD37 antibody-drug conjugate [patent_app_type] => utility [patent_app_number] => 18/411436 [patent_app_country] => US [patent_app_date] => 2024-01-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 16 [patent_no_of_words] => 25542 [patent_no_of_claims] => 46 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 182 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18411436 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19170920 [patent_doc_number] => 20240156894 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-16 [patent_title] => STABLE ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/408826 [patent_app_country] => US [patent_app_date] => 2024-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13051 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18408826 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19793332 [patent_doc_number] => 12234262 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2025-02-25 [patent_title] => Vaccinia virus recombinant A33R protein and kit for diagnosing antibodies against orthopoxvirus comprising the same [patent_app_type] => utility [patent_app_number] => 18/393436 [patent_app_country] => US [patent_app_date] => 2023-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 10183 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18393436 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19379438 [patent_doc_number] => 20240269308 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-15 [patent_title] => PRODRUGS OF TOPOISOMERASE I INHIBITOR FOR ADC CONJUGATIONS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/393062 [patent_app_country] => US [patent_app_date] => 2023-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 59300 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -41 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18393062 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19170985 [patent_doc_number] => 20240156959 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-16 [patent_title] => COMBINATION THERAPY FOR THE TREATMENT OF CANCER COMPRISING AN ANTl-EGFR ANTIBODY AND AN AXL-INHIBITOR [patent_app_type] => utility [patent_app_number] => 18/544514 [patent_app_country] => US [patent_app_date] => 2023-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18851 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18544514 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19441452 [patent_doc_number] => 12091694 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-17 [patent_title] => Fc fusion molecules and uses thereof [patent_app_type] => utility [patent_app_number] => 18/512556 [patent_app_country] => US [patent_app_date] => 2023-11-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 6 [patent_no_of_words] => 160010 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18512556 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19563565 [patent_doc_number] => 12138316 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-11-12 [patent_title] => Anti-B7H3 antibody-drug conjugate and use thereof [patent_app_type] => utility [patent_app_number] => 18/511591 [patent_app_country] => US [patent_app_date] => 2023-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 29 [patent_no_of_words] => 33400 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18511591 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19519885 [patent_doc_number] => 12121584 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-22 [patent_title] => Conjugate molecules [patent_app_type] => utility [patent_app_number] => 18/509504 [patent_app_country] => US [patent_app_date] => 2023-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 35915 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18509504 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19233786 [patent_doc_number] => 20240190978 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-13 [patent_title] => COMPOSITIONS AND METHODS FOR IMMUNOMODULATORY BIFUNCTIONAL FUSION MOLECULES [patent_app_type] => utility [patent_app_number] => 18/509203 [patent_app_country] => US [patent_app_date] => 2023-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24754 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18509203 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19186246 [patent_doc_number] => 20240165159 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-23 [patent_title] => COMPOSITIONS AND METHODS FOR CAR T CELL THERAPY [patent_app_type] => utility [patent_app_number] => 18/494613 [patent_app_country] => US [patent_app_date] => 2023-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 86779 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 88 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18494613 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19032603 [patent_doc_number] => 20240082418 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-14 [patent_title] => METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE [patent_app_type] => utility [patent_app_number] => 18/381450 [patent_app_country] => US [patent_app_date] => 2023-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23784 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18381450 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18938229 [patent_doc_number] => 20240033368 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-01 [patent_title] => PREPARATION AND PURIFICATION METHOD OF ANTIBODY DRUG CONJUGATE INTERMEDIATE [patent_app_type] => utility [patent_app_number] => 18/375175 [patent_app_country] => US [patent_app_date] => 2023-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5324 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 588 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18375175 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19003683 [patent_doc_number] => 20240067754 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-29 [patent_title] => MATERIALS AND METHODS FOR IMPROVED SINGLE CHAIN VARIABLE FRAGMENTS [patent_app_type] => utility [patent_app_number] => 18/461191 [patent_app_country] => US [patent_app_date] => 2023-09-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45533 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18461191 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19125816 [patent_doc_number] => 20240131169 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-25 [patent_title] => CLIPTAC COMPOSITION [patent_app_type] => utility [patent_app_number] => 18/461170 [patent_app_country] => US [patent_app_date] => 2023-09-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29758 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 141 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18461170 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19018822 [patent_doc_number] => 20240074993 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-07 [patent_title] => METHODS OF TREATING OR PREVENTING AN ATTENTION DISORDER, COGNITIVE DISORDER, AND/OR DEMENTIA ASSOCIATED WITH A NEURODEGENERATIVE DISORDER [patent_app_type] => utility [patent_app_number] => 18/242036 [patent_app_country] => US [patent_app_date] => 2023-09-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11089 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 237 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18242036 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19331371 [patent_doc_number] => 20240245801 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-25 [patent_title] => TARGETING TUMOR CELLS WITH CHEMOTHERAPEUTIC AGENTS CONJUGATED TO ANTI-MATRIPTASE ANTIBODIES BY IN VIVO CLEAVABLE LINKING MOIETIES [patent_app_type] => utility [patent_app_number] => 18/460243 [patent_app_country] => US [patent_app_date] => 2023-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14397 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 161 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18460243 [rel_patent_id] =>[rel_patent_doc_number] =>)